Download - Bayer HealthCare

expertise. The current R&D focus in blood glucose
monitoring includes ease-of-use, meter accuracy,
and software to simplify data capture and analysis. In
radiology and interventional, the division is focused on
investments in informatics, contrast media, fluid delivery
systems, interventional therapeutic catheters and other
accessories to deliver innovative integrated solutions to
customers. R&D activities focus on contrast agents for
high field MRI and low radiation CT; solutions to improve
diagnostic outcome and radiology workflow efficiency;
equipment service; and vascular intervention systems for
treating constricted or blocked blood vessels. The
division’s expanded global network of leading clinical
researchers supports R&D activities through innovative
clinical studies.
Research and development in the Animal Health Division
is concentrated on the identification and registration of
new active ingredients for applications in companion
and farm animals. Another priority is the development of
innovative formulations and new applications for existing
research and Development Projects (Phase iii)*
Aflibercept Treatment of diabetic macular edema
active ingredients. The close collaboration with the re-
search departments of Bayer HealthCare Pharma and
Bayer CropScience offers a unique competitive advantage
thanks to the opportunities to share data and
research results. In all of Bayer Animal Health’s developments,
the focus is always on user friendliness and
safety for both humans and animals. The division’s main
development sites are located in Monheim (Germany),
Shawnee (USA) and Auckland (new Zealand).
In the Analgesics category, Bayer Aspirin has been
a leader in pain relief for over 110 years. The new Bayer
Advanced Aspirin represents the most exciting Aspirin
innovation to date in the United States. Launched by the
Consumer Care Division in 2011, the product was the
result of more than five years of research and development
and uses breakthrough patented technology to
reduce the Aspirin particles into micro-particles. This
next generation of Aspirin targets younger, more active
consumers.
Aflibercept Prevention of abnormal retinal angiogenesis following
pathological myopia
BAY 86-6150 (rFVIIa mutein) Treatment of hemophilia A (Phase II/III)
BAY 94-9027 (rFVIII mutein) Treatment of hemophilia A
Ciprofloxacin Inhale Treatment of pulmonary infections
LCS-16 (ULD LnG Contraceptive System) Intrauterine contraception, duration of use: up to 5 years
Prasterone ** Treatment of vulvovaginal atrophy
Rivaroxaban Prevention of major adverse cardiac events (MACE)
Sodium deoxycholate *** Injection for reduction of submental fat
Sorafenib Treatment of breast cancer
Sorafenib Treatment of liver cancer, adjuvant therapy
Sorafenib Treatment of kidney cancer, adjuvant therapy
Sorafenib Treatment of thyroid cancer
Tedizolid Treatment of complicated skin and lung infections
rESEArCH AnD DEvEloPMEnT
* as of February 11, 2013
** prasterone = vaginorm
*** sodium deoxycholate =
ATX-101
The nature of drug discovery and
development is such that not all
compounds can be expected to
meet the predefined project
goals. It is possible that any or all
of the projects listed above may
have to be discontinued due to
scientific and / or commercial
reasons and will not result in
commercialized products. It is also
possible that the requisite Food
and Drug Administration (FDA),
European Medicines Agency
(EMA) or other regulatory
approvals will not be granted for
these compounds.
19